Agios Pharmaceuticals saw mitapivat revenue jump 259% year-over-year to $44.7 million in Q2 2026, driven by the launch for thalassemia treatment. The company is leveraging mitapivat's platform across rare diseases like PK deficiency, thalassemia, and potentially sickle cell disease. Agios holds $965 million in cash to support pipeline growth and reduce dilution risk ahead of a key FDA decision expected November 1, 2026, for sickle cell disease. Risks include regulatory uncertainty, commercial execution challenges, and competition from Novo Nordisk’s etavopivat.
Berkshire Hathaway has allocated 29.7% of its $356 billion investment portfolio to just two artificial intelligence stocks. This significant concentration underscores the growing confidence and interest in AI technologies as key drivers of future gro...
Applied Materials shares have dropped about 32% from their all-time highs amid concerns over the semiconductor equipment cycle and high-profile short selling by investor Michael Burry. Despite the recent steep correction, the company benefits from st...
SK Hynix reported a 257% year-over-year revenue increase in Q2 2026, fueled by strong demand for AI-related DRAM and NAND memory products. The company benefits from a leading position in the high-bandwidth memory market and maintains robust financial...
Bitcoin transfer volume among retail investors making transactions under $10,000 increased by 9.36% over the past 30 days, reversing a steep decline seen earlier in 2026. This rise comes during a period of stable Bitcoin prices around $64,000 to $65,...
Advanced Micro Devices (AMD) has been upgraded to a Buy rating following a 107% year-over-year surge in Data Center revenue, which now accounts for 58% of the company's total revenue. AMD's AI infrastructure products—EPYC, Instinct, and Helios—are cr...
